The Potential Role of Serotonergic Hallucinogens in Depression Treatment
Life July 29, 2021 Dominika Psiuk, Emilia Nowak, Krystian Cholewa et al. 13 citations
A systematic review of 14 clinical trials from the last decade found that psychedelic substances, particularly psilocybin, can reduce depressive symptoms as measured by several psychological scales, with effects often lasting months after the last session. One study showed psilocybin has comparable efficacy to escitalopram for treating depression. No serious adverse events were reported. The authors suggest psychedelics hold great potential for depression therapy, pending further research to address current study limitations.